profit from every $100 of sales.
$0$100
BriaCell Therapeutics
$3.51-2.23% today
-65.3% in 1 year
1-year low $2.741-year high $12.64
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What BriaCell Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2021 to $0 in 2024, with -$4.79 million of profit last year.
SalesProfit
BriaCell Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BriaCell Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads BriaCell Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -7 | -15 | -23 | -33 | |
| -14 | -27 | -23 | -5 | |
| -14 | -27 | -20 | -5 | |
| – | -259.50 | -195.00 | -43.68 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 58 | 43 | 27 | 6 |
| Cash | 57 | 41 | 21 | 1 |
| Total debt | 0 | – | – | – |
| Total liabilities | 30 | 32 | 31 | 9 |
| 28 | 10 | -4 | -2 | |
| – | 0 | 0 | 0 | |
| -39.2% | -205.3% | – | – | |
| -49.9% | -259.8% | 537.5% | 201.1% |
Cash flow
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| -8 | -12 | -24 | -24 | |
| – | – | – | 0 | |
| -8 | -12 | -24 | -25 | |
| Dividends paid | – | – | – | – |
| 0 | 10 | 0 | 0 | |
| 2 | 3 | 2 | 2 |
Valuation
- –
- –
- –
- 0.4×
- –
- –
- 0.6×
- -132.0%
- -123.3%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -123.6%
- 56.3%
- -221.7%
- -129.4%
- -123.6%
- –
Growth
- –
- –
- −16.3%
- –
- +58.1%
Financial health
- -0.8×
- 0.00
- 0.0%
- -504.1×
- 10.10
- 10.10
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 872
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 10, 2026 | -2.58 | -4.84 | +46.7% |
| Dec 11, 2025 | -4.35 | – | – |
| Oct 27, 2025 | -10.49 | -12.11 | +13.4% |
| Jun 16, 2025 | -16.40 | -17.60 | +6.8% |
| Mar 12, 2025 | -23.30 | -19.40 | −20.1% |
| Dec 16, 2024 | -32.98 | -0.30 | −10,893.3% |
| Jul 31, 2024 | -0.73 | – | – |
| Jun 14, 2024 | 16.49 | -82.46 | +120.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
69Pass
Benjamin Graham
81Pass
Philip Fisher
45No pass
Peter Lynch
62Pass
Joel Greenblatt
52No pass
Charlie Munger
51No pass
Terry Smith
53No pass
Questions about BriaCell Therapeutics
Is BriaCell Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BriaCell Therapeutics AI analysis
What does BriaCell Therapeutics do?
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. It is in Biotechnology.
Does BriaCell Therapeutics pay a dividend?
No. BriaCell Therapeutics does not pay a dividend at the moment.
Is BriaCell Therapeutics stock halal?
Yes. BriaCell Therapeutics passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has BriaCell Therapeutics stock done over the past year?
Down 65.3% over the past twelve months, to $3.51. It traded between $2.74 and $12.64 and is 72.2% below its high.
Who are BriaCell Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with BriaCell Therapeutics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.